biotech firms expanding glp-1 use beyond diabetes and obesity 2025

biotech firms expanding glp-1 use beyond diabetes and obesity 2025 How a Pre-Revenue Anti-Obesity Became Pharma's Most Coveted Target: Inside the $10bn Bidding War for Metsera – Bocconi Students M&A Circle ADA '26: Lilly's dominance, Pfizer's

Name: biotech firms expanding glp-1 use beyond diabetes and obesity 2025 How a Pre-Revenue Anti-Obesity Became Pharma's Most Coveted Target: Inside the $10bn Bidding War for Metsera – Bocconi Students M&A Circle ADA '26: Lilly's dominance, Pfizer's
Brand: eric-jean.com
SKU: 14050697518
Price: 28.59 USD
Availability: InStock
Rating: 4.5481 (8 reviews)

SKU: 14050697518

4.5

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Sep 27 - Oct 2

Description

However, similar to GnRH agonist, GnRH antagonist is associated with hypoestrogenic adverse effects, which require the addition of estradiol and norethindrone acetate (add-back therapy) to attenuate the hypoestrogenic effect (Schlaff et al., 2020)